Johnson & Johnson
People also watch:PGMRKKOPFEXOM
124.82-0.07 (-0.06%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close124.89
Bid124.80 x 900
Ask124.81 x 700
52wk Range81.79 - 126.07
Day's Range124.80 - 125.55
Avg Vol (3m)7,062,514
As of 1:39 PM EDT. NYSE Real Time Price. Market open.
  • TheStreet.com1 hour ago

    Top 10 Dividend Aristocrats to Buy at a Discount Now

    These 10 dividend aristocrat stocks offer an average high yield of 3% and have increased dividends for 46 consecutive years on average.

  • American City Business Journals2 hours ago

    Tokai's shares tumble as it halts prostate-cancer drug trial

    Tokai Pharmaceuticals announced this morning that it’s stopping a late-stage trial of its potential prostate cancer therapy because it has determined it probably won’t show the drug works. Boston-based Tokai (TKAI) said its drug, called galeterone, “will likely not succeed in meeting its primary endpoint of demonstrating an improvement in radiographic progression-free survival” in certain patients who have a shortened version of a so-called androgen receptor — about a fifth of the patient population with prostate cancer. It was data from a mid-stage trial of the drug showing it worked in patient with the so-called “AR-V7 splice variant” that helped Tokai raise $98 million in its September 2014 IPO.